Zheng Huang

Zheng Huang has gained extensive work experience in the biopharmaceutical industry. Their most recent role is as the Executive Director of Portfolio & PMO at I-Mab Biopharma, starting in 2022. Prior to that, they served as the President Assistant and Head of Portfolio Management and Strategic Alliance at Abbisko Therapeutics from 2020 to 2022. Before joining Abbisko Therapeutics, Zheng worked at Innovent Biologics as the Associate Director and Head of Portfolio Management, assisting the CEO's office in strategic decision-making from 2018 to 2020.

Zheng's earlier experience includes working at Novartis Institutes for BioMedical Research, where they had various roles such as Global Program Manager, Investigator, Scientist, and Research Associate from 2011 to 2018. Their responsibilities at Novartis included leading global oncology early phase programs, providing strategic leadership for development plans, and conducting research in oncology, epigenetics, drug discovery, target therapy, and translational medicine.

Prior to their industry roles, Zheng completed their PhD at the Shanghai Institutes for Biological Science, Chinese Academy of Sciences from 2005 to 2011.

Zheng Huang received a Ph.D in cell biology and biochemistry from the Chinese Academy of Sciences between 2005 and 2011. Prior to that, between 2001 and 2005, they obtained a Bachelor of Science (B.S.) in life science from Fudan University.